Invention Grant
- Patent Title: Hydroxypyridoxazepines as NRF2 activators
-
Application No.: US17429088Application Date: 2020-02-11
-
Publication No.: US11945826B2Publication Date: 2024-04-02
- Inventor: Mark Elban , Michal Pawel Glogowski , Michael Clinton Koetting , Brian Griffin Lawhorn , Jay M. Matthews , Jaclyn Renee Patterson
- Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
- Applicant Address: GB Middlesex
- Assignee: GlaxoSmithKline Intellectual Property Development Limited
- Current Assignee: GlaxoSmithKline Intellectual Property Development Limited
- Current Assignee Address: GB Stevenage
- Agent Nora L. Stein
- International Application: PCT/IB2020/051100 2020.02.11
- International Announcement: WO2020/165776A 2020.08.20
- Date entered country: 2021-08-06
- Main IPC: C07D498/04
- IPC: C07D498/04 ; C07D498/10
Abstract:
The present invention relates hydroxypyridoxazepine compounds, methods of making them, pharmaceutical compositions containing them and their use as Nrf2 activators. In particular, the invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof, or a tautomer thereof, or a hydrate thereof.
Public/Granted literature
- US20220204526A1 HYDROXYPYRIDOXAZEPINES AS NRF2 ACTIVATORS Public/Granted day:2022-06-30
Information query
